Analysts Set Sotera Health (NASDAQ:SHC) PT at $15.70

Shares of Sotera Health (NASDAQ:SHC) have been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.70.

A number of equities analysts have recently issued reports on the company. Barclays upped their price objective on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Tuesday, August 6th.

Sotera Health Stock Performance

Sotera Health stock opened at $15.48 on Friday. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46. The firm has a market capitalization of $4.38 billion, a PE ratio of 81.47 and a beta of 2.07. The firm’s 50 day simple moving average is $15.84 and its 200 day simple moving average is $13.36.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.15 by $0.04. The business had revenue of $277.00 million during the quarter, compared to analysts’ expectations of $266.45 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The firm’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.19 earnings per share. As a group, analysts expect that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Company insiders own 55.12% of the company’s stock.

Institutional Investors Weigh In On Sotera Health

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in Sotera Health by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 9,565,862 shares of the company’s stock valued at $161,185,000 after buying an additional 52,802 shares during the last quarter. State of Michigan Retirement System boosted its stake in Sotera Health by 28.7% in the 1st quarter. State of Michigan Retirement System now owns 30,500 shares of the company’s stock worth $366,000 after purchasing an additional 6,800 shares in the last quarter. State of Alaska Department of Revenue grew its position in Sotera Health by 20.6% during the 1st quarter. State of Alaska Department of Revenue now owns 13,490 shares of the company’s stock valued at $162,000 after purchasing an additional 2,300 shares during the last quarter. Principal Financial Group Inc. increased its stake in Sotera Health by 27.6% during the 1st quarter. Principal Financial Group Inc. now owns 468,500 shares of the company’s stock valued at $5,627,000 after purchasing an additional 101,430 shares in the last quarter. Finally, Retirement Systems of Alabama raised its holdings in Sotera Health by 26.0% in the first quarter. Retirement Systems of Alabama now owns 156,157 shares of the company’s stock worth $1,875,000 after buying an additional 32,269 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.